Caroline Palomeque
Stock Analyst at Maxim Group
(2.61)
# 1,958
Out of 4,829 analysts
9
Total ratings
55.56%
Success rate
16.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Caroline Palomeque
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DARE Daré Bioscience | Downgrades: Hold | n/a | $2.88 | - | 2 | Aug 14, 2024 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $59 | $35.65 | +65.50% | 1 | Sep 7, 2023 | |
| KRYS Krystal Biotech | Initiates: Buy | $154 | $139.43 | +10.45% | 1 | Sep 7, 2023 | |
| HALO Halozyme Therapeutics | Reinstates: Buy | $58 | $66.58 | -12.89% | 1 | Mar 27, 2023 | |
| ASND Ascendis Pharma | Assumes: Buy | $166 | $154.43 | +7.49% | 1 | Aug 30, 2022 | |
| DNLI Denali Therapeutics | Initiates: Buy | $39 | $14.80 | +163.51% | 1 | Jun 23, 2022 | |
| RGNX REGENXBIO | Initiates: Buy | $61 | $7.97 | +665.37% | 1 | Jun 23, 2022 | |
| AVXL Anavex Life Sciences | Initiates: Buy | $40 | $8.55 | +367.84% | 1 | Jun 23, 2022 |
Daré Bioscience
Aug 14, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.88
Upside: -
Harmony Biosciences Holdings
Sep 7, 2023
Initiates: Buy
Price Target: $59
Current: $35.65
Upside: +65.50%
Krystal Biotech
Sep 7, 2023
Initiates: Buy
Price Target: $154
Current: $139.43
Upside: +10.45%
Halozyme Therapeutics
Mar 27, 2023
Reinstates: Buy
Price Target: $58
Current: $66.58
Upside: -12.89%
Ascendis Pharma
Aug 30, 2022
Assumes: Buy
Price Target: $166
Current: $154.43
Upside: +7.49%
Denali Therapeutics
Jun 23, 2022
Initiates: Buy
Price Target: $39
Current: $14.80
Upside: +163.51%
REGENXBIO
Jun 23, 2022
Initiates: Buy
Price Target: $61
Current: $7.97
Upside: +665.37%
Anavex Life Sciences
Jun 23, 2022
Initiates: Buy
Price Target: $40
Current: $8.55
Upside: +367.84%